Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up-Reference-Cited by-同舟云学术

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

Published:2024-08 Issue:8 Volume:19 Page:1228-1241
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Gadgeel Shirish M.,Rodríguez-Abreu Delvys,Halmos Balazs,Garassino Marina C.,Kurata Takayasu,Cheng Ying,Jensen Erin,Shamoun Mark,Rajagopalan Kumar,Paz-Ares Luis

Publisher

Elsevier BV

Reference22 articles.

1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

3. National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version);Chin J Cancer Res,2022

4. The Japanese Lung Cancer Society guideline for non-small cell lung cancer, stage IV;Akamatsu;Int J Clin Oncol,2019

5. Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS;Wu;Ann Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial;European Journal of Cancer;2024-11

2. Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC;Journal of Thoracic Oncology;2024-08

3. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review;Frontiers in Oncology;2024-06-17

4. Comprehensive analysis: efficacy of pembrolizumab as an initial therapy for PD-L1 negative NSCLC;einstein (São Paulo);2024